Hypha Labs, Inc.

Hypha Labs Targets Disruptive Mushroom Active Ingredient Production

Hypha Labs (OTCQB: FUNI) is promoting its Mushroom Accelerator biomanufacturing platform, which it says produces mushroom-derived biological material in about eight days versus an approximately 90-day conventional cultivation benchmark. The company targets potential production cost savings of up to 80% via automation and its proprietary Micropearls starting material for nutraceutical, supplement, and functional-beverage ingredients. A collaboration with Mycology Resources combines Hypha's production technology with mushroom genetics and extraction expertise to support commercial scale-up; no revenue, orders, or commercial commitments were disclosed.

•0mo ago

The Functional Mushroom Revolution Has Begun

Hypha Labs is positioning itself to support the growth of the functional mushroom industry by developing automated production technologies aimed at improving scalability and consistency. The company is currently building its proprietary Mushroom Accelerator platform to reduce production time and enhance commercial-scale manufacturing capabilities. CEO Stone Douglass stated that manufacturing innovation is becoming the key competitive advantage for leaders in the emerging functional mushroom sector.

•3mo ago

Hypha Labs (OTCQB:FUNI) Sees State-by-State Psilocybin Reform Creating the Next Major Growth Opportunity

Hypha Labs views the expanding state-level adoption of psilocybin programs as a significant long-term opportunity for manufacturing infrastructure, comparing the trend to the early days of the cannabis market. CEO Stone Douglass stated that the company is focused on building scalable mushroom production technology to support growing demand in therapeutic and functional markets. The company aims to position itself as a supplier of infrastructure rather than a competitor developing pharmaceutical compounds.

•3mo ago

Trump Psychedelic Executive Order Accelerates Industry Growth

Hypha Labs announced it is positioned to benefit from President Trump's executive order accelerating research and regulatory review for psychedelic therapies. The executive order aims to fast-track access to treatments like psilocybin and MDMA for mental health conditions such as PTSD and depression. CEO Stone Douglass highlighted the company's AI-driven Mushroom Accelerator™ platform, noting it reduces production time to approximately eight days.

•6mo ago